G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021
G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call scheduled for May 5, 2021, at 4:30 p.m. ET, to provide a corporate and financial update for Q1 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call scheduled for May 5, 2021, at 4:30 p.m. ET, to provide a corporate and financial update for Q1 2021. The call can be accessed via domestic and international dialing. G1 Therapeutics, based in Research Triangle Park, focuses on developing next-generation therapies for cancer, including its first product, COSELA™ (trilaciclib), and has a clinical pipeline targeting various solid tumors such as colorectal, breast, lung, and bladder cancers.
Positive
- Scheduled Q1 2021 corporate and financial update webcast indicates transparency.
- Focus on innovative cancer therapies with a deep clinical pipeline.
Negative
- None.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was -0.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2021 on Wednesday, May 5, 2021 at 4:30 p.m. ET.
The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 2509548. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
G1 Therapeutics™ and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.
Contact:
Will Roberts
G1 Therapeutics, Inc.
Vice President, Investor Relations & Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.